Rosiglitazone Warfarin

CYP2C9 20 10 Celecoxib Diclofenac Fluoxetine Fluvastatin Ibuprofen Irbesarten Naproxen Amitriptyline Phenytoin Tolbutamide Torsemide S-warfarin Rosiglitazone Amiodarone Fluconazole Fluvoxamine Fluvastatin Isoniazid Sertraline Sulfaphenazole Trimethoprin Zafirlukast Rifampin Clotrimazole Carbamazepine Hyperforin Phenobarbital Ritonavir... 

Rosiglitazone has been studied in combination with acarbose, digoxin, metformin, nifedipine, ranitidine, warfarin, and oral contraceptives [67,72] There have been no clinically significant effects on the pharmacokinetics of any of these agents in combination with rosiglitazone. 

Pioglitazone does not appear to alter the pharmacokinetics or anticoagulant effect of warfarin or phenprocoumon. Rosiglitazone did not affect the pharmacokinetics of warfarin. 

Rosiglitazone has been found to have no clinically relevant effect on the steady-state pharmacokinetics of warfarin. ... 

Controlled studies have shown no interaction between pioglitazone and warfarin or phenprocoumon, or between rosiglitazone and warfarin. This suggests that coumarin dose adjustments are unlikely to be needed when these antidiabetics are used. 

A 71-year-old man with type 2 diabetes taking amlodipine, warfarin, valsartan, hydrochlorothiazide, atenolol, and rosiglitazone was given fenofibrate. The HDL cholesterol fell from 0.96 to 0.60 mmol/1 but rose to 0.80 mmol/1 on changing the rosiglitazone to pioglitazone. 

A 64-year-old woman with type 2 diabetes taking metoprolol aspirin, niacin, warfarin, simvastatin, rosiglitazone, and metformin was given fenofibrate. The HDL cholesterol fell from 1.09 to 0.44 mmol/1. The fenofibrate was withdrawn and the HDL rose to 1.09 mmol/1. 

---